- Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders
- Sosei Heptares eligible to receive an upfront payment, research funding and potential near-term development milestones of up to £34 million (US$44 million), potential downstream payments of up to £336 million (US$437 million) and tiered royalties
PR Newswire
TOKYO and CAMBRIDGE, England, Dec. 21, 2020